Shanghai Ark Biopharmaceutical Co., Ltd.
18
2
2
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
5.6%
1 terminated/withdrawn out of 18 trials
90.0%
+3.5% vs industry average
17%
3 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AK0406 Injection in Healthy Adult Participants
Role: lead
A Clinical Study of AK0610
Role: lead
A Study of AK0529 in Adults Patients Hospitalized With RSV Infection
Role: lead
A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants
Role: lead
Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects
Role: lead
A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD
Role: lead
Viral Inhibition in Children for Treatment of RSV
Role: lead
A Study of AK0529 in Chinese Infants Hospitalized With RSV
Role: lead
A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis
Role: lead
A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar
Role: lead
A Study of AK3280 in Chinese Healthy Volunteers
Role: lead
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects
Role: lead
A Study to Assess the Effect of AK3280 on Renal Function in Healthy Subjects
Role: lead
A Study of AK0529 to Evaluate Pharmacokinetics and Safety in Chinese Healthy Volunteers
Role: lead
Anti-RSV Study in Chinese Patients (ASCENT)
Role: lead
A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529
Role: lead
A Study of AK0529 in Infants Hospitalized With RSV
Role: lead
Safety, Tolerability and PK Study of AK0529 in Healthy Human
Role: lead
All 18 trials loaded